EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024

Mark G Wise, Irina Alekseeva, Fakhar Siddiqui, Katherine Young, Mary R Motyl, Daniel F Sahm

Frontiers in Cellular and Infection Microbiology · 12.05.2026 · 16

DOI: 10.3389/fcimb.2026.1827575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 12.05.2026. Verfasst von Mark G Wise und 5 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, Schaumburg, IL, United States. Hauptthemen laut MEDLINE: Tazobactam, Imipenem, Cephalosporins, Azabicyclo Compounds. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents.

Methods

From 2020 to 2024, two clinical laboratories in Kuwait and one each in Qatar, the United Arab Emirates, and Oman (participated in 2022–2024 only) collected up to 250 consecutive Gram-negative isolates per year from patients with bloodstream, intra-abdominal, lower respiratory tract, and urinary tract infections. MICs were determined by CLSI broth microdilution and interpreted with 2025 EUCAST breakpoints. Most imipenem, imipenem/relebactam, and ceftolozane/tazobactam non-susceptible isolates were interrogated for their acquired β-lactamase content.

Results

Ceftolozane/tazobactam was active against 85.6% of the Enterobacterales ( n = 3,603), including 92.0% of ESBL-positive, non-CRE (non-carbapenem-resistant Enterobacterales) phenotype Escherichia coli and 91.6% of ESBL-positive, non-CRE phenotype Klebsiella pneumoniae , but was poorly active against MDR (multiple-drug resistant) isolates (21.6% susceptible). In total, 90.6% of non- Morganellaceae Enterobacterales ( n = 3,421) were imipenem/relebactam-susceptible, including 95.6% of the E. coli and 80.7% of the K. pneumoniae . Pseudomonas aeruginosa isolates ( n = 1,347) were highly susceptible to both ceftolozane/tazobactam and imipenem/relebactam, with 91.2% and 89.0% inhibited, respectively. Both ceftolozane/tazobactam and imipenem/relebactam retained activity against ≥70% of cefepime-resistant, ceftazidime-resistant, and piperacillin/tazobactam-resistant P. aeruginosa . Ceftolozane/tazobactam inhibited the greatest percentage of meropenem-resistant P. aeruginosa (66.9%) among comparator β-lactam antimicrobials. Molecular characterization showed that the majority of both the imipenem/relebactam- and ceftolozane/tazobactam-resistant Enterobacterales harbored the NDM metallo-β-lactamase (MBL). Most of the imipenem/relebactam-resistant P. aeruginosa characterized did not possess acquired β-lactamases, while the majority of those resistant to ceftolozane/tazobactam carried a variety of acquired enzymes, including MBLs (IMP, VIM, NDM) and ESBLs (VEB, GES).

Conclusion

Recent clinical isolates of Enterobacterales collected in the Arabian Gulf region were highly susceptible to imipenem/relebactam, while both imipenem/relebactam and ceftolozane/tazobactam exhibited excellent activity against P. aeruginosa. However, the incidence of MBLs in the region remains a significant concern for future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TazobactamImipenemCephalosporinsAzabicyclo CompoundsAnti-Bacterial AgentsGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsPseudomonas aeruginosaOmanUnited Arab EmiratesKuwaitbeta-LactamasesDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

EnterobacteralesPseudomonas aeruginosaSMARTceftolozane/tazobactamimipenem/relebactam

Substanzen

TazobactamImipenemCephalosporinsAzabicyclo CompoundsAnti-Bacterial Agentsceftolozane, tazobactam drug combinationrelebactambeta-Lactamases

Autor:innen und Institutionen

  • IHMA, Schaumburg, IL, United States.
  • MSD, Dubai, United Arab Emirates.
  • Merck & Co., Inc., Rahway, NJ, United States.

Zitieren

APA

Wise, M. G., Alekseeva, I., Siddiqui, F., Young, K., Motyl, M. R., & Sahm, D. F. (2026). Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1827575

Vancouver

Wise MG, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1827575

BibTeX
@article{Wise2026,
  author = {Wise, Mark G and Alekseeva, Irina and Siddiqui, Fakhar and Young, Katherine and Motyl, Mary R and Sahm, Daniel F},
  title = {Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1827575}
}
Kostenlos starten →